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Macrophages accumulate in kidney glomeruli and
interstitium of patients with diabetic nephropathy in
response to monocyte chemoattractant protein-1 (MCP-1);
a chemokine produced by both tubular epithelial and
mesangial cells (MCs). Vitamin D and its analogs have been
shown to have renoprotective effects; however, there are few
studies involving diabetic nephropathy. We explored
mechanisms by which 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) can be renoprotective by measuring MCP-1
expression in MCs. Using a luciferase reporter assay, we
found that high glucose (HG)-induced MCP-1 transcription
and that this induction is blocked by 1,25(OH)2D3.
Electrophoretic mobility shift and chromatin
immunoprecipitation assays showed that HG increased the
p65/p50 binding to the two NF-jB sites within the promoter.
This was suppressed by 1,25(OH)2D3, but this decrease was
reversed by overexpression of p65. 1,25(OH)2D3 was found to
stabilize IjBa leading to an inhibition of p65 translocation to
the nucleus and subsequent reduction of NF-jB binding. In
primary MCs prepared from vitamin D receptor knockout
animals, basal MCP-1 levels were elevated but not affected by
1,25(OH)2D3. The analog paricalcitol inhibited the induction
and activity of MCP-1 while ameliorating glomerulosclerosis
in streptozotocin-diabetic mice. Our results suggest that
1,25(OH)2D3 might block hyperglycemia-induced renal injury
by blunting NF-jB activation.
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Diabetic nephropathy is the most common renal complica-
tion of diabetes mellitus that often leads to end-stage renal
disease and a high rate of mortality.1 Although diabetic
nephropathy is generally not considered an immune disease,
increasing evidence from experimental and clinical studies
has unveiled a pathological role of macrophages in develop-
ment of renal injury. Early glomerular macrophage infiltra-
tion is reported to precede glomerulosclerosis, and
macrophage accumulation is correlated with progression of
renal injury in a number of diabetes animal models.2–5
Similarly, accumulation of macrophages within the glomeruli
and interstitium is also found in the kidney specimen of
patients with diabetic nephropathy,6,7 supporting a damaging
role of macrophage in development of diabetic nephropathy.
Macrophages may contribute to glomerulosclerosis and renal
structural damage by secretion of inflammatory chemokines,
cytokines, and fibrogenic factors, release of proteolytic
enzymes, and production of reactive oxygen species. Targeting
macrophage-mediated renal injury is considered to have
therapeutic potentials for intervention of diabetic nephropathy.
Monocyte chemoattractant protein (MCP)-1 is a chemo-
kine produced by mesangial cells (MCs) and renal tubular
cells that plays a key role in the recruitment of macrophages
into the kidney. Numerous studies have demonstrated the
importance of MCP-1 upregulation in the initiation and
progression of diabetic nephropathy. Urinary MCP-1 levels
are significantly elevated in patients with diabetic nephro-
pathy and correlate to the extent of albuminuria.8,9 Mice
lacking MCP-1 develop less severe diabetic renal injury,
which is associated with marked reduction in glomerular and
interstitial macrophage accumulation.10 Pharmacological
blockade of the renin–angiotensin system, which alleviates
proteinuria in diabetic rats, suppresses renal MCP-1 expres-
sion.11 Production of MCP-1 by human and murine MCs or
tubular epithelial cells increases in response to a number of
factors thought to be involved in glomerular injury, such as
lipopolysaccharide, interleukin-1, tumor necrosis factor-a,
and interferon-g;12–15 more importantly, high glucose (HG)
and advanced glycation end product also directly stimulate
MCP-1 expression in MCs.16,17 It has been shown that
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nuclear factor-kB (NF-kB), the dimeric transcription factor
believed to play a role in renal diseases,18 is critically involved
in HG- and lipopolysaccharide-induced MCP-1 upregulation
in MCs.15,16
1,25-dihydroxyvitamin D3 (1,25(OH)2D3), the hormonal
form of vitamin D, plays indispensable roles in the regulation
of renal functions such as calcium, phosphate, and sulfate
metabolism.19–22 1,25(OH)2D3 also negatively regulates the
renin–angiotensin system,23 which is considered to play a key
role in development of diabetic nephropathy.24 Vitamin D
deficiency has been linked to chronic renal disease in human
patients, and vitamin D has been shown to have renopro-
tective roles. In subtotally nephrectomized rats, administra-
tion of 1,25(OH)2D3 significantly decreases albuminuria,
podocyte hypertrophy, and glomerulosclerosis.25 22-oxacal-
citriol, a low-calcemic vitamin D analog, inhibits MC
proliferation in vitro26 and ameliorate glomerular injury in
rats with glomerulonephritis.27 However, few studies have
directly addressed the role of vitamin D in diabetic
nephropathy.
As the initial effort to explore the potential of vitamin D
in protection against renal injury caused by hyperglycemia,
we investigated the effect of 1,25(OH)2D3 on HG-induced
MCP-1 expression in cultured MCs because of the import-
ance of MCP-1 in diabetic nephropathy. Our data indicate
that 1,25(OH)2D3 suppresses MCP-1 expression by blocking
the activation of NF-kB, suggesting that vitamin D may
protect the kidney by reducing macrophage infiltration.
RESULTS
Given the importance of MCP-1 in macrophage infiltration
in diabetic nephropathy, we used an MC line as a model to
investigate the effect of vitamin D on MCP-1 expression. As
shown in Figure 1, when MCs were shifted to the HG (30 mM
glucose) media for 24 h, MCP-1 mRNA expression was
induced by about 40% in MC cultures. Treatment of MCs
with 2 108 M of 1,25(OH)2D3 for 24 h markedly reduced
MCP-1 mRNA levels, with about 30% reduction in the low
glucose (LG, 5 mM glucose) state and about 65% reduction in
the HG state (Figure 1a and b). Therefore, vitamin D is able
to suppress the induction of MCP-1 by HG in MCs. The basal
level of vitamin D receptor (VDR) in MCs was relatively low,
which was markedly induced by 1,25(OH)2D3 treatment at
both the mRNA and protein levels under both LG and HG
conditions. HG had little effect on the VDR level (Figure 1c
and d). VDR induction by 1,25(OH)2D3 has been docu-
mented in previous studies.28
To explore the molecular mechanism underlying the
repression of MCP-1 induction, we cloned the 2.5 kb 50-
flanking region of the mouse MCP-1 gene spanning 2466 to
þ 67. This promoter region contains two putative NF-kB
binding sites at 2374 and 2348, designated as NF-kBa (50-
GGGAACTTCC-30) and NF-kBb (50-GGGAATTTCC-30)
sites, respectively (Figure 2a). Overall, the mouse and rat
DNA sequences within the 2.5 kb 50-flanking region share
74% homology, the homology within 100 bp surrounding the
two putative NF-kB binding sites is 97%, and the core
sequence of these two kB sites was identical in the mouse and
rat MCP-1 gene promoter.15 The promoter fragment was
cloned into pGL3 luciferase reporter vector, and the pMCP-
1-Luc plasmid was used to transfect MCs. Consistent with the
changes in the mRNA level, HG induced the MCP-1
promoter activity by about 70%, and 1,25(OH)2D3 treatment
significantly reduced the MCP-1 promoter activity by
approximately 20% and 40% in the LG and HG conditions,
respectively (Figure 2b). These results indicate that vitamin D
suppresses the increase of MCP-1 gene transcription induced
by HG.
Previous studies have demonstrated that NF-kB activation
plays an important role in HG induction of MCP-1 in MCs.16
As mentioned above, two putative NF-kB binding sites,
NF-kBa and NF-kBb, were found in the mouse MCP-1 gene
promoter (Figure 2a). A previous study has shown that the
two NF-kB sites at similar positions in the rat MCP-1 gene
promoter mediate lipopolysaccharide-induced MCP-1 ex-
pression in rat tubular epithelial cells.15 To assess whether the
NF-kB sites in the mouse gene promoter bind to NF-kB
proteins, electrophoretic mobility shift assays (EMSAs) were
performed using 32P-labelled double-stranded probes corre-
sponding to sequences specific to NF-kBa and NF-kBb. As
shown in Figure 3, both sites specifically interacted with
NF-kB p65/p50 heterodimers in MC nuclear extracts. The
bindings at both sites were supershifted by anti-p65 antibody
(Figure 3a and b) or anti-p50 antibody (data not shown), and
competed off by excess unlabeled probe of the same sequence
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Figure 1 | Effect of 1,25(OH)2D3 on MCP-1 mRNA expression in
mesangial cells. MCs cultured in low glucose (LG) or high glucose
(HG) media were untreated or treated with 2 108 M of 1,25(OH)2D3
(VD) for 24 h. Total RNAs were extracted and MCP-1 mRNA levels
were determined by (a) real-time reverse transcription-PCR (RT-PCR)
and (b) Northern blot analyses. *Po0.01 vs LG; **Po0.01 vs
corresponding untreated samples. 1,25(OH)2D3 stimulates VDR
expression at both mRNA and protein levels, yet HG has little
effects on the VDR level, as shown by (c) real-time PCR analyses
and (d) Western blotting assays. *Po0.01.
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(NF-kBa or NF-kBb) or the canonical NF-kB sequence
(NF-kBc, 50-GGGGCATTTCCC-30), but not by excess cold
probes bearing mutations at the core NF-kB sites (NF-kBam
or NF-kBbm). Interestingly, it required only three times
more cold NF-kBc probe to compete off the nuclear proteins
binding on site a, but needed 20 times more for site b
(Figure 3a and b). Judging from the intensity of the bands
and the amount of unlabeled probes required for a complete
competition, it is clear that site b has a higher affinity for
p65/p50 than site a. This is probably due to the fact that the
site b sequence is more similar to the canonical NF-kB
binding site than site a. Therefore, it is likely that NF-kBb is
the predominant cis-DNA element that mediates the NF-kB
activity. This is consistent with the previous observation that
site B in rat MCP-1 promoter plays the dominant role in
lipopolysaccharide-mediated MCP-1 transcription in rat
tubular cells.15
We have shown previously that VDR has an inhibitory
effect on NF-kB activation.29 Therefore, EMSAs were further
used to study the effect of 1,25(OH)2D3 on NF-kB DNA
binding activity in MCs. As shown in Figure 4, HG markedly
induced NF-kB binding to both site a and b, but the
induction was much more robust for site b; treatment with
1,25(OH)2D3 markedly attenuated the HG-induced NF-kB
binding on both sites (Figure 4). Indeed, in the presence of
1,25(OH)2D3, the NF-kB binding activity stimulated by HG
was reduced to the baseline level of the LG culture (compare
lanes 3 and 6, 9 and 12). As activation of NF-kB by HG has
been shown to mediate MCP-1 upregulation in MCs,16 this
result suggests that 1,25(OH)2D3 blunts HG-induced MCP-1
expression by blocking the NF-kB binding activity.
We assessed further whether 1,25(OH)2D3 blocks NF-kB
DNA binding in live MCs by performing chromatin
immunoprecipitation (ChIP) assays. Because the a and b
sites are separated by only 16 bp, in the ChIP assays we used
PCR primers that flank both the a and b sites to quantify NF-
kB p65 and p50 binding to both sites (Figure 5a). At the LG
culture condition, there was little p65 or p50 binding to the
NF-kB sites; HG drastically stimulated p65 and p50 binding
to these sites, whereas 1,25(OH)2D3 almost completely
blocked the HG-induced p65/p50 binding (Figure 5b). To
confirm the inhibitory effect of vitamin D on the induction
of NF-kB binding activity, MCs were co-transfected with
pMCP-1-Luc reporter and increasing amounts of pcDNA-
p65 plasmid in luciferase reporter assays. Indeed, over-
expression of p65 rescued and reversed the inhibition of
MCP-1 promoter activity by 1,25(OH)2D3 in a dose-
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Figure 2 | Effect of 1,25(OH)2D3 treatment on MCP-1 promoter
activity. (a) Schematic map of MCP-1 promoter-luciferase reporter
construct. The mouse MCP-1 gene promoter from 2466 to þ 67
contains two NF-kB binding sites at 2374 (NF-kBa) and
2348 (NF-kBb), as indicated. (b) Luciferase reporter assays. MCs
were transfected with pMCP-1-Luc reporter plasmid in serum-free LG
media. After 6 h, the cells were exposed to LG or HG media
containing 10% FBS in the presence or absence of 2 108 M of
1,25(OH)2D3 (VD). Luciferase activity was determined after 24 h.
*Po0.01 vs LG; **Po0.05 vs corresponding untreated sample.
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Figure 3 | Binding of NF-jB protein complex to the NF-jB sites
in the MCP-1 gene promoter. Nuclear extracts isolated from MCs
were used to incubate with (a) 32P-labelled NF-kBa or (b) NF-kBb
probes in EMSAs. The incubation was also carried out in the presence
of anti-p65 antibody (ap65), or competed with an excess amount
(3–20-old) of unlabeled probe of consensus NF-kB sequence (NF-kBc),
mutant NF-kBa (NF-kBam) or NF-kBb (NF-kBbm) as indicated. C, No
nuclear extract control; NS, nonspecific band; SS, supershift band;
arrows indicate NF-kB-specific bands.
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Figure 4 | Suppression of NF-jB DNA binding by 1,25(OH)2D3.
MCs were pretreated with or without 2 108 M of 1,25(OH)2D3 (VD)
for 15 h, and then shifted to NG, LG or HG media for 90 min. Nuclear
extracts were prepared and incubate with 32P-labelled NF-kBa or
NF-kBb probes as indicated in EMSAs. NS, nonspecific band;
arrows indicate NF-kB-specific bands.
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dependent manner (Figure 5c), confirming that 1,25(OH)2D3
targets NF-kB in MCP-1 regulation.
We investigated further the effect of 1,25(OH)2D3 on p65
nuclear translocation, which is required for NF-kB activa-
tion. Immunofluorescent staining of MCs with anti-p65
antibody showed that HG-induced p65 nuclear translocation
in 30 min (compare Figure 6a and e); in the presence of
1,25(OH)2D3, p65 nuclear translocation was largely blocked
(Figure 6c and g). This observation was confirmed by
Western blot analysis of nuclear extracts shown in Figure 6i.
The nuclear extracts were isolated from MCs pretreated with
1,25(OH)2D3 for 24 h. An increase in p65 accumulation in
the nuclear extracts was seen when the cells were exposed to
HG media for 30 min in the absence of 1,25(OH)2D3;
however, no increase was detected in the presence of
1,25(OH)2D3 (Figure 6i). Inhibition of p65 translocation
was also apparent in the LG state.
To explore further the mechanism underlying the inhibi-
tion of p65 nuclear translocation, we determined the effect of
1,25(OH)2D3 on IkBa, the major inhibitor of NF-kB that
binds to NF-kB and blocks its nuclear translocation. As
shown in Figure 7, 20 min after MCs were shifted to the HG
media, the IkBa protein level was reduced (compare lanes 5
and 7) and returned to the basal level at 120 min;
interestingly, in the presence of 1,25(OH)2D3, the level of
the IkBa protein was markedly upregulated regardless of the
LG or HG media (Figure 7a and b), consistent with the fact
that 1,25(OH)2D3 inhibited the p65 nuclear translocation in
both media (Figure 6i). Therefore, 1,25(OH)2D3 appeared to
suppress NF-kB activity by inducing or stabilizing, at least in
part, the IkBa protein in MCs.
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Figure 5 | Inhibition of NF-jB p65/p50 DNA binding by
1,25(OH)2D3 in live MCs. (a) Schematic map showing the location of
the primers used in the ChIP assays. (b) ChIP assays. MCs cultured in
serum-free LG media were pretreated with or without 2 108 M of
1,25(OH)2D3 (VD) for 24 h, and the cells were then exposed to
FBS-containing LG and HG media for 30 min before the ChIP assays.
Sonicated chromatins were precipitated with anti-p65 or anti-p50
antibody. Input represents 5% total chromatin isolated from the cells.
Note HG markedly induces p65/p50 binding to the NF-kB sites, which
is completely blocked by 1,25(OH)2D3. (c) Luciferase reporter assays.
MCs were co-transfected with pMCP-1-Luc and increasing amounts
of pcDNA-p65 plasmid (from 10 to 200 ng) and then treated with (þ )
or without () 2 108 M of 1,25(OH)2D3 as indicated. Luciferase
activity was determined after 24 h.
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Figure 6 | Blocking of NF-kBp65 nuclear translocation by 1,25(OH)2D3. MCs cultured in LG media were pre-treated (c, d, g, and h)
with or (a, b, e and f) without 2 108 M of 1,25(OH)2D3 for 24 h. The cells were then exposed to (a–d) LG or (e–f) HG media for 30 min, fixed
and stained with (a, c, e and g) anti-p65 antibody or (b, d, f and h) with 4-diamidino-2-phenylindole (DAPI) to visualize the nucleus. The
cells were observed under a fluorescent microscope. (i) MCs were pretreated with or without 2 108 M of 1,25(OH)2D3 for 24 h, and shifted
to LG or HG media for 30 min. Nuclear extracts were isolated and the levels of nuclear p65 were assessed by Western blotting.
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Another question that we addressed was the effect of the
VDR status on the MCP-1 level. To this end, we isolated
primary MCs from wild type and VDR null-mutant mice,
and cultured them under the LG and HG conditions.
Interestingly, the basal MCP-1 level in VDR(/) MCs
grown in the LG media was markedly elevated (by about
150%) compared with VDR(þ /þ ) MCs (Figure 8a);
consistently, the basal level of MCP-1 in the kidney of
VDR(/) mice was also higher than that of VDR(þ /þ )
mice (Figure 8b), confirming the repressive role of VDR in
MCP-1 expression. As expected, 1,25(OH)2D3 treatment
suppressed MCP-1 expression in VDR(þ /þ ) cells in both
LG and HG media; however, 1,25(OH)2D3 had no effect on
MCP-1 expression in VDR(/) cells, regardless of LG or
HG media (Figure 8a). Therefore, inhibition of MCP-1
expression by 1,25(OH)2D3 is clearly mediated by VDR.
Interestingly, induction of MCP-1 by HG was less robust in
VDR(/) cells (by about 30%) than in VDR(þ /þ ) cells
(by about 100%).
To explore the effect of vitamin D in vivo, we treated
streptozotocin (STZ)-induced diabetic mice with paricalcitol,
a low-calcemic vitamin D analog.30 As shown in Figure 9, 10
weeks after STZ treatment, MCP-1 expression in the renal
cortex was markedly increased (by 35% vs nondiabetic
controls), and paricalcitol treatment basically blunted MCP-1
induction associated with diabetes (Figure 9a). We also
quantified monocyte/macrophage infiltration in the glomer-
uli by immunostaining with anti-F4/80 antibody, a macro-
phage-specific antibody. As expected, the number of
F4/80-positive cells in the glomeruli was markedly increased
in the STZ-induced diabetic mice (by more than fourfold),
and the increase in F4/80-positive cells was partially
normalized by paricalcitol treatment (Figure 9b). Morpho-
logically, the diabetic mice developed glomerular sclerosis
with increased periodic acid-Schiff-positive extracellular
matrix synthesis and increased mesangial matrix area in the
glomeruli, and paricalcitol was able to ameliorate the
morphological deterioration (Figure 9c and d). Consistently,
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Figure 9 | Renoprotective effect of paricalcitol in diabetic mice.
Wild type CD-1 male mice were induced to diabetes by STZ injection
(50 mg/kg), followed by treatment with paricalcitol (P) (1.5 mg/kg) or
vehicle (V) for 10 weeks. (a) Renal cortex RNAs were extracted and the
relative levels of MCP-1 mRNA expression were determined by
real-time RT-PCR. (b) The number of F4/80-positive cells per
glomerulus in the kidney is determined by immunostaining using
anti-F4/80 antibody. (c) Representative periodic acid-Schiff staining
of glomerular morphology. (d) Semiquantitative measurement of
glomerular matrix fraction as % of the total glomerular surface.
(e) Fibronectin (FN) protein levels in the kidney lysates were
determined by Western blotting. Control, nondiabetic mice;
*Po0.05 vs control; **Po0.05 vs STZþV.
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fibronectin, a major extracellular matrix protein, was induced
in diabetic mice but virtually normalized by paricalcitol
(Figure 9e). These observations indicate that vitamin D can
suppress the synthesis and activity of MCP-1 and ameliorate
the glomerular injury in diabetic mice.
DISCUSSION
Hyperglycemia is the major determinant for the development
and progression of diabetic nephropathy in both type 1 and 2
diabetes mellitus.31,32 Diabetic nephropathy is characterized
by glomerulosclerosis, tubulointerstitial fibrosis, and albu-
minuria, which eventually lead to renal failure. There is
increasing evidence from clinical and animal studies that
suggests macrophage infiltration, which is highly stimulated
by MCP-1 produced by the MCs and tubular cells, as an
important pathogenic factor contributing to the kidney
injury in diabetic nephropathy. In this study, we demonstrate
that vitamin D suppresses HG-induced MCP-1 upregulation
in MCs by blocking the activation of NF-kB, and vitamin D
analog can inhibit the synthesis and activity of MCP-1 and
ameliorate the glomerular injury in diabetic mice. These data
suggest that vitamin D may protect against renal injury in
diabetic nephropathy by preventing or reducing macrophage
infiltration. These data provide a molecular basis to extend
the study to more preclinical and clinical settings of diabetic
nephropathy.
As a key mediator for macrophage infiltration, MCP-1 is
upregulated by NF-kB, a major proinflammatory transcrip-
tional regulator.33 In this regard, it is interesting to note that
the rat and mouse MCP-1 gene promoters are highly
conserved in the region surrounding the two NF-kB binding
sites. It has been shown previously that HG stimulates
MCP-1 expression in MCs through activation of NF-kB.16 In
this study, we demonstrate by EMSA and ChIP assays that
HG increases MCP-1 expression by inducing p65/p50
binding to the NF-kB binding sites in the mouse MCP-1
gene promoter. As a HG-induced chemokine, MCP-1 is a
potential therapeutic target for prevention of macrophage-
induced renal injury in diabetic nephropathy.
In this context, our finding that 1,25(OH)2D3 suppresses
MCP-1 upregulation induced by HG is highly significant.
1,25(OH)2D3 effectively attenuates the MCP-1 induction at
both mRNA and transcriptional levels by blocking p65/p50
binding to the NF-kB sites in the gene promoter. Although
exactly how vitamin D disrupts this protein–DNA interaction
remains unclear, our data indicate that at least part of the
mechanism is to increase or stabilize IkBa, thus arresting p65
nuclear translocation. In fact, this appears to be a common
mechanism, as a similar stimulatory or stabilizing effect of
1,25(OH)2D3 on IkBa has also been reported in fibroblasts,
keratinocytes, and pancreatic islet cells.29,34,35 Clearly, more
studies are needed to elucidate how 1,25(OH)2D3 regulates
IkBa. On the other hand, VDR may physically interact with
p65 to potentially block p65 binding to DNA, as reported
previously in fibroblasts and osteoblasts.29,36 However, by co-
immunoprecipitation, we failed to detect VDR–p65 associa-
tion in MCs regardless of the presence or absence of
1,25(OH)2D3 (data not shown). Thus, VDR–p65 physical
association appears to be cell-specific. Furthermore, previous
works have also shown that 1,25(OH)2D3 may modulate
NF-kB activity by downregulation of RelB transcription37 or
by suppressing the increase in p50, its precursor p105, and c-
rel proteins in activated lymphocytes.38 Regardless of the
mechanism, the observations that 1,25(OH)2D3 suppresses
the induction of MCP-1 and the activation of the renin–
angiotensin system in diabetic nephropathy models (Sun
et al. J Am Soc Nephrol 2005; 16: 3A) provide a good
molecular basis to explain the renoprotective effect of
vitamin D.39
MCP-1 is abundantly expressed in MCs in the basal state
when cultured in the LG media. Interestingly, 1,25(OH)2D3
also suppresses the basal MCP-1 expression in the LG
condition. Because the basal expression is not dependent on
NF-kB (the ChIP assays show little p65/p50 binding to the
NF-kB sites in the LG state; Figure 5), 1,25(OH)2D3 must
suppress the basal MCP-1 expression by a NF-kB-indepen-
dent mechanism. Given the importance of MCP-1 in the
pathogenesis of many disorders, it is worthwhile to elucidate
this regulatory mechanism in future studies.
As expected, 1,25(OH)2D3 has no effects on MCP-1
expression in VDR(/) cells, indicating that VDR is
absolutely required to mediate the repressive action of
1,25(OH)2D3. The fact that the basal MCP-1 level is elevated
in VDR(/) MCs as well as in VDR null mice confirms the
inhibitory role of VDR in MCP-1 expression. It is interesting
that the basal MCP-1 level in VDR(/) MCs is higher than
even the HG-induced level in VDR(þ /þ ) cells, whereas the
induction of MCP-1 by HG is less robust in VDR(/) cells
(Figure 8). Although the exact reason underlying these
observations is unclear, one explanation may be the
limitation of the MC capacity to synthesize MCP-1. MCP-1
is a high abundant protein in MCs, and usually it is more
difficult for cells to increase the level of high abundant
proteins. In VDR(/) cells, the MCP-1 level is already 2.5
times the baseline, which may limit the magnitude of
upregulation by HG. Alternatively, the high MCP-1 may be
owing to overactivation of NF-kB in the absence of VDR.
Indeed, we have shown that in fibroblasts, NF-kB activity is
significantly elevated in the absence of VDR.29 As the NF-kB
binding sites are mostly occupied, the ability of HG to induce
NF-kB DNA binding becomes limited, leading to decreased
MCP-1 upregulation.
In addition to the in vitro studies that investigate the
mechanism underlying the effect of vitamin D on MCP-1
induction, we have also demonstrated that a low-calcemic
vitamin D analog, paricalcitol, is able to inhibit the
expression and activity of MCP-1 and ameliorate the
glomerular scelerosis in the kidney of diabetic mice. These
in vitro and in vivo studies provide a good basis for further
exploring the therapeutic potentials of vitamin D analogs in
the intervention and prevention of diabetic nephropathy in
the future. As a major complication of diabetes, diabetic
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nephropathy often leads to end-stage renal failure and high
mortality, and finding effective treatment and prevention for
diabetic nephropathy has been a major challenge facing
modern medicine. In this regard, the data presented here
supports more studies to investigate the renoprotective
properties of vitamin D and its analogs in diabetic
nephropathy.
MATERIALS AND METHODS
Isolation of primary MCs
Glomeruli were isolated from VDR(þ /þ ) and VDR(/) mouse
kidneys by collagenase digestion followed by differential sieve
filtration, and MCs were selected using D-valine media as reported
previously.40,41 The isolated glomeruli were cultured in minimum
essential medium/D-valine medium containing 20% fetal bovine
serum (FBS) and 1 antibiotic–antimycotic (Invitrogen Corp.,
Carlsbad, CA, USA) at 5% CO2 and 371C. Fibroblasts died off after
about 3–4 weeks in the D-valine media,40 and the culture was passed
for up to three passages before being changed to Dulbecco’s
modified Eagle’s medium (DMEM)/F12 media containing 10% FBS,
insulin, and antibiotics. The primary MCs were used between
passages 5–10.
MC culture
Mouse MC line (SV40 MES 13; ATCC, Manassas, VA, USA) and
primary MC were maintained routinely in DMEM/F12 (containing
B15 mM glucose, designated as normal glucose (NG) media)
supplemented with 10% heat-inactivated FBS in 5% CO2 incubator
at 371C. For HG stimulation, the cells were synchronized in serum-
free DMEM containing 5 mM glucose for 48 h, and then changed to
DMEM containing 5 mM glucose and 10% FBS (LG media) or to
DMEM containing 30 mM glucose and 10% FBS (HG media], and
cultured for different times as indicated in the presence or absence
of 1,25(OH)2D3.
Cloning of mouse MCP-1 gene promoter
The 2.5 kb mouse MCP-1 gene promoter DNA sequence corre-
sponding to nucleotides 2466 to þ 67 was amplified by PCR from
mouse genomic DNA template. The nucleotides are numbered
based on the sequence of the rat MCP-1 gene promoter published
previously.15 The PCR primers are 50-TCCGGCCCATGAGAG
AACTGCTT-30 (forward) and 50-TGGCTTCAGTGAGAGTTGG
CTGGT-30 (reverse). The MCP-1 promoter nucleotide sequence
was confirmed by DNA sequencing, and cloned into pGL3 basic
luciferase vector (Promega Corp., Madison, WI, USA) to generate
reporter plasmid, pMCP-1-Luc.
Luciferase reporter assays
MCs were co-transfected with pCMV-bgal and pMCP-1-Luc
plasmids using Lipofectamine 2000 (Invitrogen) in serum-free LG
media. Six hours after transfection, the cells were exposed to LG or
HG media supplemented with FBS in the presence or absence of
2 108 M 1,25(OH)2D3 for 24 h. The cells were lysed and luciferase
activity determined using the Luciferase Assay Systems (Promega).
The luciferase activity was normalized with b-galactosidase.42
Real-time reverse transcriptase-polymerase chain reaction
(RT-PCR)
First-strand cDNAs were synthesized from total RNAs using
MML-V reverse transcriptase (Invitrogen) and hexanucleotide
random primers. The cDNAs were used as the template for real-
time PCR amplification with mouse MCP-1-specific primers, 50-
GCTCAGCCAGATGCAGTTAA-30 (forward) and 50-TCTTGAGC
TTGGTGACAAAAACT-30 (reverse). Real-time PCR was performed
in an Applied Biosystems 7300 Real Time PCR System using a SYBR
green PCR reagent kit (Applied Biosystems, Foster City, CA, USA).43
The change in mRNA levels is determined based on the formula
2DDCt . The relative amount of the sample mRNA was normalized to
b-2 microglobulin.
Western blotting
Proteins were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and electroblotted onto Immobilon-P mem-
branes. The membranes were probed with primary and secondary
antibodies as detailed previously.44
Northern blotting
Total RNAs were separated on 1% agarose gels containing
formaldehyde and transferred onto a nylon membrane. Hybridiza-
tion was performed at 651C according to Church and Gilbert45 with
MCP-1 cDNA probe labeled with 32P-dATP. The relative amount of
MCP-1 mRNA was normalized with 36B4 mRNA.44
EMSA
Nuclear extracts were prepared from MCs following the established
method.46 For EMSA, double-stranded oligodeoxynucleotide probes
were end-labeled with g-32P-ATP using polynucleotide kinase. The
NF-kBa probe is 50-AGGGTCTGGGAACTTCCAATACTGC-30, and
the NF-kBb probe is 50-CCTCAGAATGGGAATTTCCACGCTC-30.
The labeled probe was incubated with nuclear extracts (10 mg) at
room temperature for 30 min in the presence of 100 mg/ml
polyd(I:C), and the mixture was electrophoresed on a 4%
nondenatured polyacrylamide gel.46 The specificity of protein–DNA
interaction was confirmed by competition with excess unlabeled
probes of the same sequence, with the canonical NF-kB probe,
NF-kBc (50-AGTTGAGGGGCATTTCCCAGGC-30; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), or with mutated probes
NF-kBam (50-AAGGGTCTGGGAACTcggAATACTGCCTCAGAAT-30)
and NF-kBbm (50-TACTGCCTCAGAATGGccATTTCCACGCTCT
TAT-30). Incubation with anti-p65 or anti-p50 antibody (Santa Cruz
Biotechnology) was used to confirm the presence of these proteins
in the DNA–protein complex.
ChIP assays
NF-kB binding to the MCP-1 gene promoter in MCs was
determined by ChIP assays using a commercial kit from Upstate
(Lake Placid, NY, USA). Briefly, MCs were pretreated with or
without 2 108 M 1,25(OH)2D3 in serum-free media for 24 h, and
then exposed to the LG or HG media containing 10% FBS for
30 min. The cells were immediately treated with 1% formaldehyde to
cross-link histones to DNA. The cells were lysed and sonicated to
shear the chromatins. The sonicated chromatins were incubated
with anti-p65 or anti-p50 antibody. After overnight reaction, the
chromatin–antibody complex was precipitated with protein-A–
agarose beads. The complex was digested with proteinase K, and
the DNA isolated from the complex was subject to PCR
amplification using primers flanking the two NF-kB binding sites
in the MCP-1 gene promoter: 50-CAAGCCAGAGCTCAGAC
TAGGCCT-30 (forward) and 50-CACAGGAGGCAGCGCAAATGT
GA-30 (reverse). The PCR products were run on a 1.5% agarose gel
and stained with ethidium bromide.
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Immunostaining
MCs pretreated with 2 108 M 1,25(OH)2D3 overnight on cover-
slips were switched to the LG or HG media. After 30 min, the cells
were fixed with 4% paraformaldehyde for 30 min and stained with
anti-p65 antibody as described previously.29
Animal studies
Two-month-old CD-1 male mice were injected intraperitoneal with
STZ (Sigma-Aldrich, St Louis, MO, USA, dissolved in 10 mM Na
citrate, pH 4.2) or the citrate vehicle at a daily dose of 50 mg/kg for 5
consecutive days. Blood glucose levels were monitored weekly with
One-Touch Glucometer (Johnson and Johnson, New Brunswick, NJ,
USA). The STZ-treated mice were diabetic in 2 weeks after STZ
injection (fasting blood glucose¼ 502721 mg/dl). At this time, the
STZ-treated mice were randomly separated into two groups. One
group was injected intraperitoneal with paricalcitol (Abbott
Laboratories, Abbott Park, IL, USA) at 1.5 mg/kg (dissolved in
propylene glyco/water/ethanol¼ 60:30:10) thrice a week, and the
other group treated with the vehicle. All mice were killed 10 weeks
after STZ treatment. For each mouse, one kidney was used for
histological analyses, and the other used for preparation of total
RNAs and lysates. Paraffin-embedded sections were stained with
hematoxylin and eosin or with periodic acid-Schiff according to
standard procedures. Glomerular matrix fraction was semiquanti-
fied by measuring the periodic acid-Schiff-positive area as
percentage of the total glomerular surface as described previously.47
Frozen sections were immunostained with anti-F4/80 antibody
(AbD Serotec, Raleigh, NC, USA). F4/80-positive cells in glomeruli
were counted under a microscope. At least 30 glomeruli in each
mouse were surveyed. MCP-1 mRNA levels were quantified by real-
time RT-PCR. Fibronectin levels in the kidney lysates were
determined by Western blot analysis. The Institutional Animal Care
and Use Committee at the University of Chicago approved the use of
mice.
ACKNOWLEDGMENTS
This work was supported by NIH grants DK59327, DK73183, and
American Diabetes Association grant 7-05-RA-80 (to YCL).
REFERENCES
1. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes:
a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;
34: 795–808.
2. Lavaud S, Michel O, Sassy-Prigent C et al. Early influx of glomerular
macrophages precedes glomerulosclerosis in the obese Zucker rat model.
J Am Soc Nephrol 1996; 7: 2604–2615.
3. Sassy-Prigent C, Heudes D, Mandet C et al. Early glomerular macrophage
recruitment in streptozotocin-induced diabetic rats. Diabetes 2000; 49:
466–475.
4. Chow F, Ozols E, Nikolic-Paterson DJ et al. Macrophages in mouse type 2
diabetic nephropathy: correlation with diabetic state and progressive
renal injury. Kidney Int 2004; 65: 116–128.
5. Young BA, Johnson RJ, Alpers CE et al. Cellular events in the
evolution of experimental diabetic nephropathy. Kidney Int 1995; 47:
935–944.
6. Nguyen D, Ping F, Mu W et al. Macrophage accumulation in human
progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11:
226–231.
7. Furuta T, Saito T, Ootaka T et al. The role of macrophages in diabetic
glomerulosclerosis. Am J Kidney Dis 1993; 21: 480–485.
8. Banba N, Nakamura T, Matsumura M et al. Possible relationship of
monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney
Int 2000; 58: 684–690.
9. Wada T, Furuichi K, Sakai N et al. Up-regulation of monocyte
chemoattractant protein-1 in tubulointerstitial lesions of human diabetic
nephropathy. Kidney Int 2000; 58: 1492–1499.
10. Chow FY, Nikolic-Paterson DJ, Ozols E et al. Monocyte chemoattractant
protein-1 promotes the development of diabetic renal injury in
streptozotocin-treated mice. Kidney Int 2006; 69: 73–80.
11. Kato S, Luyckx VA, Ots M et al. Renin–angiotensin blockade lowers MCP-1
expression in diabetic rats. Kidney Int 1999; 56: 1037–1048.
12. Grandaliano G, Valente AJ, Rozek MM et al. Gamma interferon stimulates
monocyte chemotactic protein (MCP-1) in human mesangial cells. J Lab
Clin Med 1994; 123: 282–289.
13. Rovin BH, Yoshiumura T, Tan L. Cytokine-induced production of
monocyte chemoattractant protein-1 by cultured human mesangial cells.
J Immunol 1992; 148: 2148–2153.
14. Satriano JA, Hora K, Shan Z et al. Regulation of monocyte
chemoattractant protein-1 and macrophage colony-stimulating factor-1
by IFN-gamma, tumor necrosis factor-alpha, IgG aggregates, and cAMP in
mouse mesangial cells. J Immunol 1993; 150: 1971–1978.
15. Wang Y, Rangan GK, Goodwin B et al. Lipopolysaccharide-induced MCP-1
gene expression in rat tubular epithelial cells is nuclear factor-kappaB
dependent. Kidney Int 2000; 57: 2011–2022.
16. Ha H, Yu MR, Choi YJ et al. Role of high glucose-induced nuclear
factor-kappaB activation in monocyte chemoattractant protein-1
expression by mesangial cells. J Am Soc Nephrol 2002; 13: 894–902.
17. Yamagishi S, Inagaki Y, Okamoto T et al. Advanced glycation end
product-induced apoptosis and overexpression of vascular endothelial
growth factor and monocyte chemoattractant protein-1 in
human-cultured mesangial cells. J Biol Chem 2002; 277: 20309–20315.
18. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal
disease. Kidney Int 2001; 59: 415–424.
19. DeLuca HF. The vitamin D story: a collaborative effort of basic science and
clinical medicine. FASEB J 1988; 2: 224–236.
20. Bolt MJ, Liu W, Qiao G et al. Critical role of vitamin D in sulfate
homeostasis: regulation of the sodium-sulfate cotransporter by
1,25-dihydroxyvitamin D3. Am J Physiol Endocrinol Metab 2004; 287:
E744–E749.
21. Li YC, Pirro AE, Amling M et al. Targeted ablation of the vitamin D
receptor: an animal model of vitamin D-dependent rickets type II with
alopecia. Proc Natl Acad Sci USA 1997; 94: 9831–9835.
22. Yoshizawa T, Handa Y, Uematsu Y et al. Mice lacking the vitamin D
receptor exhibit impaired bone formation, uterine hypoplasia and
growth retardation after weaning. Nature Genet 1997; 16: 391–396.
23. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative
endocrine regulator of the renin–angiotensin system. J Clin Invest 2002;
110: 229–238.
24. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and
diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274–281.
25. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3
decreases podocyte loss and podocyte hypertrophy in the subtotally
nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526–F533.
26. Abe H, Iehara N, Utsunomiya K et al. A vitamin D analog regulates
mesangial cell smooth muscle phenotypes in a transforming growth
factor-beta type II receptor-mediated manner. J Biol Chem 1999; 274:
20874–20878.
27. Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog
ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol
2001; 158: 1733–1741.
28. Zella LA, Kim S, Shevde NK et al. Enhancers located within two introns of
the vitamin D receptor gene mediate transcriptional autoregulation by
1,25-dihydroxyvitamin D3. Mol Endocrinol 2006; 20: 1231–1247.
29. Sun J, Kong J, Duan Y et al. Increased NF-{kappa}B activity in fibroblasts
lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 2006; 291:
E315–E322.
30. Malluche HH, Mawad H, Koszewski NJ. Update on vitamin D and its newer
analogues: actions and rationale for treatment in chronic renal failure.
Kidney Int 2002; 62: 367–374.
31. Group TDCaCTR. The effect of intensive treatment of diabetes on the
development and progression of long-term complications in
insulin-dependent diabetes mellitus. The Diabetes Control and
Complications Trial Research Group. N Engl J Med 1993; 329: 977–986.
32. Group UPDSU. Intensive blood-glucose control with sulphonylureas or
insulin compared with conventional treatment and risk of complications
in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes
Study (UKPDS) Group. Lancet 1998; 352: 837–853.
33. Bonizzi G, Karin M. The two NF-kappaB activation pathways and
their role in innate and adaptive immunity. Trends Immunol 2004; 25:
280–288.
34. Riis JL, Johansen C, Gesser B et al. 1Alpha,25(OH)(2)D(3) regulates
NF-kappaB DNA binding activity in cultured normal human keratinocytes
200 Kidney International (2007) 72, 193–201
o r i g i n a l a r t i c l e Z Zhang et al.: Mechanism of vitamin D inhibition of MCP-1
through an increase in IkappaBalpha expression. Arch Dermatol Res 2004;
296: 195–202.
35. Giarratana N, Penna G, Amuchastegui S et al. A vitamin D analog
down-regulates proinflammatory chemokine production by pancreatic
islets inhibiting T cell recruitment and type 1 diabetes development.
J Immunol 2004; 173: 2280–2287.
36. Lu X, Farmer P, Rubin J et al. Integration of the NfkappaB p65 subunit into
the vitamin D receptor transcriptional complex: identification of p65
domains that inhibit 1,25-dihydroxyvitamin D3-stimulated transcription.
J Cell Biochem 2004; 92: 833–848.
37. Dong X, Craig T, Xing N et al. Direct transcriptional regulation of RelB by
1alpha,25-dihydroxyvitamin D3 and its analogs: physiologic and
therapeutic implications for dendritic cell function. J Biol Chem 2003; 278:
49378–49385.
38. Yu XP, Bellido T, Manolagas SC. Down-regulation of NF-kappa B protein
levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3.
[published erratum appears in Proc Natl Acad Sci USA 1996; 93: 524] Proc
Natl Acad Sci USA 1995; 92: 10990–10994.
39. Wang Y, Zhou J, Minto AW et al. Altered vitamin D metabolism in type II
diabetic mouse glomeruli may provide protection from diabetic
nephropathy. Kidney Int 2006; 70: 882–891.
40. Gilbert SF, Migeon BR. -valine as a selective agent for normal human and
rodent epithelial cells in culture. Cell 1975; 5: 11–17.
41. Kurtz A, Jelkmann W, Sinowatz F et al. Renal mesangial cell cultures as a
model for study of erythropoietin production. Proc Natl Acad Sci USA
1983; 80: 4008–4011.
42. Qiao G, Kong J, Uskokovic M et al. Analogs of 1alpha,25-dihydroxyvitamin
D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol
2005; 96: 59–66.
43. Zheng W, Xie Y, Li G et al. Critical role of calbindin-D28k in calcium
homeostasis revealed by mice lacking both vitamin D receptor and
calbindin-D28k. J Biol Chem 2004; 279: 52406–52413.
44. Li YC, Bolt MJG, Cao L-P et al. Effects of vitamin D receptor inactivation on
the expression of calbindins and calcium metabolism. Am J Physiol
Endocrinol Metab 2001; 281: E558–E564.
45. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984;
81: 1991–1995.
46. Ausubel FM, Brent R, Kinston RE et al. Current Protocols in Molecular
Biology. John Wiley & Sons, Canada, USA, 1984.
47. Matsubara T, Abe H, Arai H et al. Expression of Smad1 is directly
associated with mesangial matrix expansion in rat diabetic nephropathy.
Lab Invest 2006; 86: 357–368.
Kidney International (2007) 72, 193–201 201
Z Zhang et al.: Mechanism of vitamin D inhibition of MCP-1 o r i g i n a l a r t i c l e
